If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Proof of Concept Programme

11 Dec 2007 11:18

Imperial Innovations Group plc11 December 2007 Imperial Innovations Group plc ("Imperial Innovations") Proof of Concept programme Imperial Innovations Group plc (AIM: IVO) today announces the creation of a newUS$1 million Proof of Concept ("PoC") programme which has been funded byShapoorji Pallonji & Company Limited ("SPCL") a diversified conglomerateincluding the oldest construction company based in India. The objective of the PoC programme is to validate and accelerate the developmentof emerging technologies at Imperial College London for spin-out opportunities.Imperial Innovations will manage the programme including the recommendation,selection, and commercial assessment of the projects. The company isparticularly interested in developing technologies with SPCL which may lead tomarket applications and follow-on joint development opportunities in India. The PoC programme will fund three to five technologies of twelve to eighteenmonths' duration over the next two years and will give priority to applicationsin the built environment, whether renewable energy or energy-efficiencyinnovations. The creation of the PoC programme with SPCL builds on Imperial Innovations'ongoing activities in India which is regarded as one of the most importanttechnology markets for the future, including the recent formation of i2india,the technology commercialisation company based in India. Susan Searle, CEO of Imperial Innovations said: "The launch of the Shapoorji Proof of Concept programme will help us qualifyinventions in our intellectual property portfolio for more focused spin-outopportunities. Pre-commercial funding is very difficult to obtain forearly-stage technologies therefore we are extremely grateful for the fundingSPCL has provided. We are also encouraged that influential companies such asSPCL turn to us to access next generation technologies." Mr. Pallonji Mistry, Chairman of Shapoorji Pallonji & Co. Ltd., Mumbai said: "We look forward to a mutually rewarding and long term relationship withImperial Innovations through promoting development projects in selected areas." -Ends- For more information contact: Imperial InnovationsSusan Searle, Chief Executive Officer +44 (0)20 7594 6591Lucy Ahfong, Marketing Communications Executive +44 (0)20 7594 6644 M:CommunicationsPatrick d'Ancona / Eleanor Williamson +44 (0)20 7153 1539 JPMorgan Cazenove (NOMAD to Imperial Innovations)Steve Baldwin +44(0)20 7588 2828 Notes to Editors About Imperial Innovations Imperial Innovations is one of the UK's leading technology transfer andcommercialisation companies. The company was founded in 1986 and its ordinaryshares admitted to trading on the AIM Market of London Stock Exchange plc inJuly 2006, raising £25 million at an offer price of 365p and £1 million by meansof a public offer. In November 2007, the company raised a further £30 million bymeans of a placing of new ordinary shares with investors. The company's integrated approach encompasses the identification of ideas,protection of intellectual property, development and licensing of technology andformation, incubation and investment in technology businesses. A wide range oftechnologies are commercialised within the areas of healthcare, energy,environment and emerging technology trends. Based at Imperial College London, the company has established equity holdings in74 technology businesses and is managing 133 commercial agreements as of 31 July2007. Imperial Innovations also commercialises technologies originating fromoutside Imperial College through incubation contracts with the Carbon Trust andWRAP and has commercialisation contracts with a number of multinationalcorporations including BAE Systems. www.imperialinnovations.co.uk About Shapoorji Pallonji & Company Ltd Shapoorji Pallonji & Company Ltd is a diversified conglomerate with businessinterests in the construction, finance, biotechnology, and energy sectors. Thecompany started 140 years ago in Mumbai as a construction company. ShapoorjiPallonji has grown from its origins as India's oldest construction company andhas developed an international reputation in delivering complex projectsincluding factories, nuclear research establishments, nuclear waste handling,scientific and research establishments, stadia and auditoria, airports, hotels,hospitals, giant skyscrapers, housing complexes, townships, water treatmentplants, roads, expressways, power plants and biotech facilities. It is thelargest private shareholder (18.5%) of TATA SONS Ltd, the Holding Company of theTATA Group. The annual turnover of the TATA Group is over US$15 billion. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Jul 20157:01 amRNS£1 million seed investment in Inflowmatix
27th Jul 20157:00 amRNS£3.0 million investment in Concirrus
23rd Jul 20151:35 pmRNSDirectorate Change
14th Jul 20157:00 amRNSFurther £50m loan facility from EIB
2nd Jul 20157:00 amRNS£4.0m funding round in Impression Technologies
1st Jul 20157:00 amRNSFirst subject enrolled in Veryan Medical's study
30th Jun 20157:00 amRNSLeads £3 million investment in Abingdon Health
8th Jun 20151:18 pmRNSDirectorate Change
3rd Jun 20157:00 amRNSInnovations leads £6m funding round in Auspherix
29th May 20157:00 amRNSAppointment of Executive Chairman at Kesios
27th May 20154:05 pmRNSHolding(s) in Company
26th May 20157:01 amRNSDivests its shares of Epigeum
19th May 20157:00 amRNS£25m Series C funding round in PsiOxus
14th May 20157:00 amRNSTopiVert starts Phase I Clinical Trial
30th Apr 20153:48 pmRNSDirector's share purchase
27th Apr 20157:00 amRNSAutifony Therapeutics recruits first trial patient
15th Apr 20157:00 amRNSInnovations leads £5.9m funding round in Yoyo
27th Mar 20157:00 amRNSHalf Yearly Report
24th Mar 20154:40 pmRNSSecond Price Monitoring Extn
24th Mar 20154:35 pmRNSPrice Monitoring Extension
18th Mar 20157:00 amRNSCell Medica granted Orphan Drug designation
13th Mar 201510:07 amRNSEdison publishes research on Imperial Innovations
27th Feb 201511:48 amRNSNotice of Results
19th Feb 20157:00 amRNSCell Medica to commence cell therapy manufacture
14th Jan 201512:13 pmRNS£18 million Series B funding round in Veryan
18th Dec 20147:00 amRNSImperial named UK's top research university
16th Dec 201411:39 amRNSResult of AGM
9th Dec 20142:55 pmRNSGrant of options under SAYE Scheme
26th Nov 20143:41 pmRNSGrant of share options
25th Nov 201410:45 amRNSReplacement Director's share purchase
25th Nov 20147:00 amRNS£50 million Series B funding round in Cell Medica
24th Nov 20144:20 pmRNSDirector's share sale
12th Nov 20147:00 amRNSPosting of Annual Report and Notice of AGM
24th Oct 20147:00 amRNSDirectorate Changes
15th Oct 20147:00 amRNSFinal Results
8th Oct 20147:00 amRNSInnovations invests £1.85m in Kesios Therapeutics
5th Sep 20141:55 pmRNSNotice of Results
13th Aug 201412:43 pmRNSDirector's share sale
15th Jul 20142:08 pmRNSDirectorate Change
7th Jul 20147:14 amRNSPortfolio company Abzena announces offer price
4th Jul 20143:36 pmRNSHolding(s) in Company
23rd Jun 20143:15 pmRNSResults of Placing
23rd Jun 20147:00 amRNSPlacing to raise £150 million
19th Jun 201412:45 pmRNSResult of General Meeting
16th Jun 20147:09 amRNSPortfolio company announces intention to float
12th Jun 20147:00 amRNSImperial Innovations invests £1.5m in Cortexica
10th Jun 20147:00 amRNS£3 million funding round for Featurespace
4th Jun 20147:00 amRNSAutifony receives funding for Phase II trial
2nd Jun 20147:00 amRNSAppointment of non-executive directors
2nd Jun 20147:00 amRNSProposed Placing to raise up to £150 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.